A phase I and pharmacokinetic study of oral 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in the treatment of advanced-stage solid cancers: a California Cancer Consortium Study

Joseph Chao; Timothy W. Synold; Robert J. Morgan; Charles Kunos; Jeff Longmate; Heinz-Josef Lenz; Dean Lim; Stephen Shibata; Vincent Chung; Ronald G. Stoller

首页> 外文期刊>Cancer Chemotherapy and Pharmacology >A phase I and pharmacokinetic study of oral 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in the treatment of advanced-stage solid cancers: a California Cancer Consortium Study

【24h】

A phase I and pharmacokinetic study of oral 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in the treatment of advanced-stage solid cancers: a California Cancer Consortium Study

机译：口服3-氨基吡啶-2-甲甲醛硫代半碳酮（3-AP，NSC＃663249）在晚期实体癌的治疗中的I期和药代动力学研究：加利福尼亚癌症协会研究

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background 3-Aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) is a novel small-molecule ribonucleotide reductase inhibitor. This study was designed to estimate the maximum tolerated dose (MTD) and oral bioavailability of 3-AP in patients with advanced-stage solid tumors.

机译：背景3-氨基吡啶-2-羧甲醛硫半碳环素（3-AP）是一种新型的小分子核糖核苷酸还原酶抑制剂。这项研究旨在评估晚期实体瘤患者中3-AP的最大耐受剂量（MTD）和口服生物利用度。

著录项

来源
《Cancer Chemotherapy and Pharmacology》 |2012年第3期|p.835-843|共9页
作者
Joseph Chao; Timothy W. Synold; Robert J. Morgan; Charles Kunos; Jeff Longmate; Heinz-Josef Lenz; Dean Lim; Stephen Shibata; Vincent Chung; Ronald G. Stoller;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词
入库时间 2022-08-18 01:47:07

相似文献

外文文献
中文文献
专利

1. A phase I and pharmacokinetic study of oral 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in the treatment of advanced-stage solid cancers: a California Cancer Consortium Study. [J] . Joseph Chao, Timothy W Synold, Robert J Morgan, Cancer chemotherapy and pharmacology. . 2012,第3期

机译：口服3-氨基吡啶-2-羧甲醛硫代半碳酮（3-AP，NSC＃663249）在晚期实体癌的治疗中的I期和药代动力学研究：加利福尼亚癌症协会研究。
2. Radiochemotherapy plus 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in advanced-stage cervical and vaginal cancers [J] . KunosC.A., RadivoyevitchT., WaggonerS., Gynecologic Oncology: An International Journal . 2013,第1期

机译：在晚期宫颈癌和阴道癌中放化疗加3-氨基吡啶-2-羧甲醛硫半乳糖（3-AP，NSC＃663249）
3. Bortezomib for patients with advanced-stage bronchioloalveolar carcinoma: a California Cancer Consortium Phase II study (NCI 7003). [J] . Ramalingam SS, Davies AM, Longmate J, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2011,第10期

机译：硼替佐米用于晚期支气管肺泡癌患者：加利福尼亚癌症协会II期研究（NCI 7003）。
4. Preparation of Curcumin Solid Lipid Nanoparticle and Studies on Its Anti- Cancer Effect and Pharmacokinetics in Rats [C] . Ying Zheng, Jiabei Sun, Shaoping Sun, The Second Asian symposium on pharmaceutical sciences and technology . 2011

机译：姜黄素固体脂质纳米粒的制备及其在大鼠体内的抗癌作用及药代动力学研究
5. Systemic Treatments in Advanced-Stage Non-Small Cell Lung Cancer in California [D] . Maguire, Frances Belda. 2018

机译：加州晚期非小细胞肺癌的全身治疗
6. A phase I and pharmacokinetic study of oral 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP NSC #663249) in the treatment of advanced stage solid cancers – A California Cancer Consortium Study [O] . Joseph Chao, Timothy W. Synold, Robert J. Morgan Jr., -1

机译：在治疗晚期固体癌症的治疗中口服3-氨基吡啶-2-羧甲醛（3-APNSC＃663249）的I和药代动力学研究。加州癌症联盟研究
7. A phase I and pharmacokinetic study of oral 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in the treatment of advanced-stage solid cancers: a California Cancer Consortium Study [O] . Joseph Chao, Timothy W. Synold, Robert J. Morgan, 2011

机译：口腔3-氨基吡啶-2-甲醛硫代甲基酮（3-AP，NSC＃663249）的I和药代动力学研究在治疗晚期固体癌症：加州癌症联盟研究

A phase I and pharmacokinetic study of oral 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in the treatment of advanced-stage solid cancers: a California Cancer Consortium Study

摘要

著录项

相似文献

相关主题

期刊订阅